Clinical Trial Update: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update investigating a combination of lenalidomide, ibrutinib, and rituximab for relapsed or refractory chronic lymphocytic leukemia or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING